

CATALYST PHARMACEUTICAL PARTNERS, INC.
Form SC 13G/A
October 01, 2012

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

Catalyst Pharmaceutical Partners, Inc.

(Name of Issuer)

Common Stock and Warrants (exercisable into Common Stock)

(Title of Class of Securities)

14888U101

(CUSIP Number)

September 28, 2012

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

14888U101
CUSIP No.

NAMES OF REPORTING PERSONS

1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Sophrosyne Capital, LLC

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2 (a)

(b)

SEC USE ONLY

3

CITIZENSHIP OR PLACE OF ORGANIZATION

4

Deleware

SOLE VOTING POWER

5 1,480,854

NUMBER OF
SHARES

SHARED VOTING POWER

BENEFICIALLY OWNED BY

6

EACH

SOLE DISPOSITIVE POWER

REPORTING PERSON WITH:

7

SHARED DISPOSITIVE POWER

8

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

9 1,480,854

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

10

1,480,854

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

11 4.66%

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

12 IA

FOOTNOTES

Common Stock and Warrants (exercisable into Common Stock)

Item 1.

(a) Name of Issuer
Catalyst Pharmaceutical Partners, Inc.

(b) Address of Issuer's Principal Executive Offices
355 Alhambra Circle

Suite 1370

Coral Gables, FL 33134

Item 2.

(a) Name of Person Filing
Benjamin J. Taylor

(b) Address of Principal Business Office or, if none, Residence
156 E 36th Street

At 2 Sniffen Court

New York, NY 10016

(c) Citizenship
USA

(d) Title of Class of Securities
Common Stock and Warrants (exercisable into Common Stock)

(e) CUSIP Number
14888U101

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is
a:

(a) £ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) £ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) £ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) £ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) £ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f) £ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g) £ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) £ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) £ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) £ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).

(k) £ A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned: 1,480,854 shares

(b) Percent of class: 4.66%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote: 1,480,854 shares

(ii) Shared power to vote or to direct the vote:

(iii) Sole power to dispose or to direct the disposition of:

(iv) Shared power to dispose or to direct the disposition of:

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

Not Applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of Group

Not Applicable

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: September 28, 2012 /s/ Benjamin J Taylor
Name: Benjamin J Taylor
Title: Managing Member

Footnotes:

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)